07:28 AM EST, 02/03/2025 (MT Newswires) -- GH Research ( GHRS ) shares were soaring over 90% in Monday's premarket session after it said a phase 2b clinical trial of GH001 for patients with treatment-resistant depression met its primary endpoint.

The biopharmaceutical company also said all secondary endpoints were met and that GH001 was well tolerated with no serious adverse events reported in the double-blind part of the trial.